1Med, a contract research organization (CRO) in the healthcare sector, has acquired LB Research. With this acquisition, 1Med is expanding its expertise in oncology and other specialist areas.
On November 15, 2024, LB Research officially became part of the 1MED Group. Founded in 2007 and headquartered in Como, Italy, LB Research is a full-service contract research organization (CRO) specializing in managing clinical trials across all phases of the clinical product lifecycle.
The company employs a highly skilled team of 24 professionals and serves a diverse client portfolio, including renowned global and Italian pharmaceutical companies. LB Research has built a strong reputation for its expertise in clinical trial management across various therapeutic areas, with a particular focus on oncology studies.
Through the acquisition of LB Research, 1MED has gained significant capabilities. Integrating LB’s expertise enhances 1MED’s offerings in clinical services for pharmaceutical and medical device trials. This strategic move also strengthens 1MED's presence in Italy and Southern Europe, consolidating its position in therapeutic areas such as cardiology and dermatology while significantly expanding its oncology expertise.
Andrea Biffi, Chair of 1MED, stated: "The integration of LB Research reinforces 1MED's reputation as a trusted partner for the MedTech and pharmaceutical industries. It fosters innovation and improves patient care worldwide. Additionally, it strengthens our footprint in Italy and Southern Europe and expands our oncology expertise."
The acquisition is backed by Apposite Capital, a key partner of 1MED. The firm views this move as a critical expansion of 1MED’s clinical CRO services across Europe. Anne-Laure Meynier, Partner at Apposite Capital, commented: "The integration of LB into the 1MED family strengthens our clinical CRO services throughout Europe and enhances our offerings with customized solutions."